Keywords: ایرینوتکان; cetuximab; colorectal cancer; cost-effectiveness; cost-utility; decision analytic modeling; Erbitux; irinotecan; panitumumab; Vectibix
مقالات ISI ایرینوتکان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Fatal tumor lysis syndrome in a patient with metastatic colon cancer after palliative chemotherapy
Keywords: ایرینوتکان; bevacizumab; chemotherapy; irinotecan; tumor lysis syndrome
A clinical PCR fragment analysis assay for TA repeat sizing in the UGT1A1 promoter region
Keywords: ایرینوتکان; UGT1A1; Pharmacogenetics; Irinotecan; Gilberts syndrome; Polymorphism
Phase I – II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Keywords: ایرینوتکان; Colorectal cancer; Ambulatory medicine; Chronotherapy; Irinotecan; Combination chemotherapyCancer colorectal; Médecine ambulatoire; Chronothérapie; Irinotecan; Polychimiothérapie
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study)
Keywords: ایرینوتکان; Ovarian cancer; Refractory; Resistant; Clear cell; Mucinous; Docetaxel; Irinotecan; TCCR, complete response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; RR, responsive rate; SD, stable disease; TC,
Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): A critical view
Keywords: ایرینوتکان; Chemotherapy; Neuroendocrine carcinoma; NEC; NET; GEP; Gastroenteropancreatic; Cisplatin; Etoposide; Carboplatin; Irinotecan
Synthesis, metabolite analysis, and in vivo evaluation of [11C]irinotecan as a novel positron emission tomography (PET) probe
Keywords: ایرینوتکان; Carbon-11; Irinotecan; Positron emission tomography (PET); Metabolite analysis; Column-switching HPLC; Solid-phase extraction
Irinotecan combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice
Keywords: ایرینوتکان; Irinotecan; Memory T cells; Alloantigen-primed mice
Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
Keywords: ایرینوتکان; Chemotherapy; Irinotecan; Oxaliplatin; Second-line; VEGF
Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs
Keywords: ایرینوتکان; Orlistat; Aspirin; Irinotecan; Liver; α/β fold hydrolases; Carboxylesterases; First passCES, carboxylesterase; CHX, cycloheximide; DMEM, Dulbecco's modified eagle medium; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PPD, pentyl carbamate of p-aminoben
A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme
Keywords: ایرینوتکان; Bevacizumab; Glioblastoma; Irinotecan; Meta-analysis
A Phase I Study of Amrubicin and Fixed Dose of Irinotecan (CPT-11) in Relapsed Small Cell Lung Cancer: Japan Multinational Trial Organization LC0303
Keywords: ایرینوتکان; Small cell lung cancer; Amrubicin; Irinotecan; Modified continuous reassessment method; Relapse
An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer
Keywords: ایرینوتکان; bevacizumab; efficacy; irinotecan; metastatic colorectal cancer; toxicity
Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
Keywords: ایرینوتکان; 5-Fluorouracil; Chemotherapy; Irinotecan; Oxaliplatin; Triplet regimen
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer
Keywords: ایرینوتکان; Small-cell lung cancer; Sunitinib; Maintenance; First-line; Irinotecan; Carboplatin
Molecular structure and vibrational spectra of Irinotecan: A density functional theoretical study
Keywords: ایرینوتکان; DFT; FTIR; FT-Raman; MEP; HOMO–LUMO; Irinotecan
Modulation of irinotecan-induced genomic DNA damage by theanine
Keywords: ایرینوتکان; Irinotecan; Theanine; Genomic damage; Oxidative DNA stress;
Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats
Keywords: ایرینوتکان; DATR; TRAIL; Synergetic toxicity; Drug combination; Chemotherapeutic; Irinotecan; Polyene paclitaxel; Oxaliplatin;
Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods
Keywords: ایرینوتکان; Polyethylene glycol (PEG) molar weight; pH-gradient method; PEG-modification method; Irinotecan; Prolonged circulation time; Antitumor effect;
Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)
Keywords: ایرینوتکان; Esophageal; Cetuximab; Cisplatin; Irinotecan; Radiotherapy
Irinotecan Injures Tight Junction and Causes Bacterial Translocation in Rat
Keywords: ایرینوتکان; tight junction; bacterial translocation; irinotecan
Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer
Keywords: ایرینوتکان; Biweekly; Cetuximab; EGFR; Irinotecan
MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection
Keywords: ایرینوتکان; MRI-monitored long-term therapeutic hydrogel; Imaging agents; Phosphazenes; Irinotecan; Brain tumors
Irinotecan induces senescence and apoptosis in colonic cells in vitro
Keywords: ایرینوتکان; Irinotecan; p53; Premature senescence; Colonic cells; Apoptosis; DNA damage
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer
Keywords: ایرینوتکان; Hyaluronic acid; Nanoparticle; Theranostics; Irinotecan; Colon cancer; Tumor targeting
Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer
Keywords: ایرینوتکان; Cetuximab; Irinotecan; Second-line treatment; Stomach cancer
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma - A phase II trial of the childhood liver tumour strategy group (SIOPEL)
Keywords: ایرینوتکان; Hepatoblastoma; Irinotecan; Clinical trial phase II; Liver cancer; Child; Camptothecin;
A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: Application to plasma and brain pharmacokinetics
Keywords: ایرینوتکان; Irinotecan; SN-38; LC–MS/MS; Pharmacokinetics; Brain distribution; Carboxylesterase
Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography–tandem mass spectrometry and its application to hepatic chemoembolization
Keywords: ایرینوتکان; Irinotecan; SN38; Camptothecin; Mass spectrometry; Ultra-high performance liquid chromatography
Alternative Chemotherapeutic Agents: Nitrosoureas, Cisplatin, Irinotecan
Keywords: ایرینوتکان; Glioblastoma; Glioma; Chemotherapy; Cisplatin; Irinotecan; Nitrosoureas; CCNU; BCNU;
The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS)
Keywords: ایرینوتکان; advanced colorectal cancer; cost-effectiveness; FOCUS trial; irinotecan; oxaliplatin;
Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model
Keywords: ایرینوتکان; Glioblastoma; Cancer; Liposomes; Irinotecan; Drug delivery; Tumor-associated vasculature
Aggregation properties and structural studies of anticancer drug Irinotecan in DMSO solution based on NMR measurements
Keywords: ایرینوتکان; NMR; Irinotecan; Aggregation; Diffusion; DMSO
Inhibition of COX-2 in Colon Cancer Modulates Tumor Growth and MDR-1 Expression to Enhance Tumor Regression in Therapy-Refractory Cancers In Vivo
Keywords: ایرینوتکان; 5-FU; 5-fluorouracil; COX; cyclooxygenase; CPT-11; irinotecan; CRC; colorectal cancer; MIP/5-FU; MIP101 cells resistant to 5-fluoruracil; MIP/CPT; MIP101 cells resistant to irinotecan; RKO/5-FU; RKO cells resistant to 5-fluorouracil; RKO/CPT; RKO cells re
Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins
Keywords: ایرینوتکان; Topoisomerase I; Hsp90; P53; Irinotecan; Topotecan; 17AAG
Topoisomerase 1 Inhibitors and Cancer Therapy
Keywords: ایرینوتکان; Topoisomerase 1; Ovarian cancer; Irinotecan; Topotecan;
Comparison of Nedaplatin and Irinotecan for Patients with Squamous and Nonsquamous Cell Carcinoma of the Lung: Meta-Analysis of Four Trials
Keywords: ایرینوتکان; Nedaplatin; Irinotecan; Squamous cell carcinoma; Lung cancer
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
Keywords: ایرینوتکان; Chemotherapy; 5 Fluorouracile; Irinotecan; Neuroendocrine tumour; Prospective; Survival
Effect of kaempferol on lipid peroxidation and antioxidant status in 1,2-dimethyl hydrazine induced colorectal carcinoma in rats
Keywords: ایرینوتکان; Antioxidant enzyme; Colorectal cancer; 1,2-dimethyl hydrazine; Irinotecan; Lipid peroxidation; Kaempferol;
Locally advanced female urethral adenocarcinoma of enteric origin: The role of adjuvant chemoradiation and brief review
Keywords: ایرینوتکان; Adjuvant chemotherapy; Chemoradiation; Irinotecan; Urethral adenocarcinoma; Urethral carcinoma輔助性化學治療; 化學及放射線治療; 喜樹鹼; 尿道腺癌; 尿道腫瘤
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer
Keywords: ایرینوتکان; Oesophagogastric cancer; Docetaxel; Irinotecan; Second-line; Chemotherapy;
Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia
Keywords: ایرینوتکان; NSCLC; Irinotecan; Paclitaxel; Gemcitabine; UGT1A1*6; UGT1A1*27
Preoperative Chemoradiation With Cetuximab, Irinotecan, and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: A Multicenter Phase II Study
Keywords: ایرینوتکان; Cetuximab; Capecitabine; Irinotecan; Preoperative chemoradiotherapy; Rectal cancer;
A Phase II Trial of Neoadjuvant Preoperative Chemoradiotherapy With S-1 Plus Irinotecan and Radiation in Patients With Locally Advanced Rectal Cancer: Clinical Feasibility and Response Rate
Keywords: ایرینوتکان; Chemoradiation; Rectal cancer; S-1; Irinotecan;
Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer
Keywords: ایرینوتکان; Carboplatin; Irinotecan; Elderly; Small-cell lung cancer;
ALCAPs induce mitochondrial apoptosis and activate DNA damage response by generating ROS and inhibiting topoisomerase I enzyme activity in K562 leukemia cell line
Keywords: ایرینوتکان; γH2AX; modified and phosphorylated histone 2A; ATM; ataexia telangiectasia mutated; PARP; poly-ADP ribose polymerase; CHK2; checkpoint kinase 2; CPT-11; irinotecan; Doxo; doxorubicin; l-NAC; l-N-acetyl-cysteine; ROS; Topoisomerase I inhibition; γH2AX; A
A Decade of Advances in Cytotoxic Chemotherapy for Metastatic Colorectal Cancer
Keywords: ایرینوتکان; 5-Fluorouracil; Cytotoxic agents; Irinotecan; Oxaliplatin
Accurate determination of the anticancer prodrug simmitecan and its active metabolite chimmitecan in various plasma samples based on immediate deactivation of blood carboxylesterases
Keywords: ایرینوتکان; Simmitecan; Chimmitecan; Irinotecan; Camptothecin; Prodrug; Carboxylesterase; Bis(4-nitrophenyl)phosphate; Pulse gradient chromatography; Matrix effects
Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer
Keywords: ایرینوتکان; 60-day mortality; Colorectal cancer; First-line treatment; Irinotecan; Oxaliplatin; Prognostic factors
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells
Keywords: ایرینوتکان; CLM3; Irinotecan; Angiogenesis; Synergism; Tyrosine kinase inhibitor